Therapeutic vaccines which include various strategies including recombinant tumor antigen proteins, peptides, tumor cells, primes the immune system to recognize tumor‐specific antigens and boost antitumor humoral and cellular immune response.129, 130 The renewed interest in therapeutic cancer vaccine has developed due to the in‐depth understanding of immune checkpoints in cancer and clinical success of immune checkpoint inhibitors along with advanced computational biology platform that enable the development of cancer neo antigen vaccination strategies. The gene discussed is LINC01194; the disease is neoplasm.